about
IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammationCombination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT studyRole of interleukin 15 and interleukin 18 in inflammatory responseLeukotrienes, mast cells, and T cellsIncreased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrateInterleukin-18: a therapeutic target in rheumatoid arthritis?Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?IntroductionEULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteriaTh17 effector cells support B cell responses outside of germinal centresNanoparticles and inflammationIL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cellsMicroRNA29a regulates IL-33-mediated tissue remodelling in tendon diseaseSerum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarctionCytokines in the pathogenesis of rheumatoid arthritisComparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived areaProstaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma productionThe pathogenesis of rheumatoid arthritisA novel method to allow noninvasive, longitudinal imaging of the murine immune system in vivo.Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, plaInterleukin-18.MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice.Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phasQuantitative detection of human tumor necrosis factor α by a resonance raman enzyme-linked immunosorbent assay.Looking through the 'window of opportunity': is there a new paradigm of podiatry care on the horizon in early rheumatoid arthritis?Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiencyInterleukin 18: a pleiotropic participant in chronic inflammation.Identification of urinary peptide biomarkers associated with rheumatoid arthritis.Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsValidated methods for assessment of subclinical atherosclerosis in rheumatology.Back to the future: oral targeted therapy for RA and other autoimmune diseases.A novel therapeutic approach targeting articular inflammation using the filarial nematode-derived phosphorylcholine-containing glycoprotein ES-62.Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review.Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis.Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritisTrial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.TNF alpha blockade in rheumatoid arthritis--time for caution or enthusiasm?Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes?Treating rheumatoid arthritis to target: recommendations of an international task force.
P50
Q24309034-671C6FB2-9001-4E35-8C37-C41D496D397EQ24674942-0322D2F6-D2E6-4374-9E98-920F78427B72Q24675082-8415F2D6-E926-47F9-908C-490C4A26A10BQ24795112-56FF99A8-8D3B-4D05-BC63-2DA3A35E164CQ24796641-B6DB66D2-93B0-4098-ADBF-2740CA0757C4Q24799490-5020B255-E2A7-4405-961B-779D9B1BED82Q24804153-F793B1B3-E514-46F0-B4A7-0E9BE3CE3828Q24804667-D2AE821D-B302-40DE-8591-50F2C3746F37Q27026582-D76E58E9-2C5D-4E46-9E4C-5053FAB52D70Q27335276-010CE6E3-7188-4FFA-AF6B-7013881B2DBCQ27694760-E97F5838-37A0-45EC-8C9A-A3C01EB6032BQ28249077-1ACE31C5-51EB-41FD-9434-0B92B97F7F67Q28260209-D3BD2989-ED4D-4B28-AD57-2682DFAC448DQ28271905-4CB40B31-32D4-40AD-979B-495175442C8BQ28303865-E0DFCADE-3ED5-4302-B915-31B2660A2279Q28364851-CC9E47C7-71CF-4624-8B9C-CEA5808E8C8DQ28586710-09E5315C-375D-401A-9890-4433D30371F3Q29614957-FEBDF4CE-259C-44E8-A187-C11B0F1D89C2Q30520629-9685CD66-542A-4CDB-93AC-CEB786DB0EDEQ30760660-6C1D8DC7-2A0F-4BC8-8DE8-043700137515Q30884172-DF72999A-F2B3-4B8A-B68E-094355D973E5Q31132757-E6BDD548-318C-4E19-9093-4EAFC0F82D44Q33659249-CAA638E8-4D87-4A5D-A45F-78ED8814F58EQ33759790-7D6B6BAA-AAE1-450F-B23B-E0861D3EBFF0Q33907217-5C973DCC-5DD2-4680-A0DE-8EDE7BC4875EQ33910884-8631D6FB-E6DF-4F16-8493-606A45DFDB62Q33953165-C52EC31A-038F-41AD-AE48-48A0796A343AQ34075303-EC8F59F2-88AA-4AC4-94B9-9E85DA75F7B8Q34092442-321C2143-628D-4520-9A02-9C373C8089EDQ34110066-3514019B-6B98-4126-ABB5-66FBAB87BC45Q34164481-95AFC66B-1DB8-47EF-8496-2E6B69A23866Q34213332-5AAB7205-50C0-4AC0-8FAD-DD896C28AC19Q34220228-CEA7C00F-E1AE-4FC6-A8B5-19BD2D879735Q34244819-2C7E74A2-1BC1-4139-90DE-64D8D5B9C288Q34283776-70EB6A7E-B3BA-477E-82E8-F39BB015D124Q34317197-0CE54D1E-42F8-4457-B8A5-C499399D26DAQ34327988-CECEF3F3-C452-4C74-82FB-8887C44665DCQ34334556-42463A41-F999-4F1E-ABDA-3A571F9DDB85Q34462325-8A37EBAE-8EBC-44A9-AE74-84DABD5650FAQ34462557-0EACA84F-3A26-43E6-9FF0-DC5A6A4B9806
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Iain B McInnes
@ast
Iain B McInnes
@en
Iain B McInnes
@es
Iain B McInnes
@nl
Iain B McInnes
@sl
type
label
Iain B McInnes
@ast
Iain B McInnes
@en
Iain B McInnes
@es
Iain B McInnes
@nl
Iain B McInnes
@sl
prefLabel
Iain B McInnes
@ast
Iain B McInnes
@en
Iain B McInnes
@es
Iain B McInnes
@nl
Iain B McInnes
@sl
P106
P21
P31
P496
0000-0002-6462-4280